Idiopathic membranous glomerulonephritis

This trial is testing an experimental therapy called FKC289 for people with a type of kidney disease called primary membranous nephropathy that has come back or not responded to standard treatment. FKC289 uses the patient's own immune cells, which are modified in the lab to recog…

Researchers are testing an experimental antibody drug called zuberitamab in people with primary membranous nephropathy, a kidney condition that causes protein to leak into the urine. The trial compares zuberitamab injections with cyclosporine, a standard immune-suppressing drug, …

This early-stage trial is testing whether a single infusion of universal STAR-T cells—a type of engineered immune cell that targets both CD19 and BCMA—can safely and effectively treat two autoimmune kidney diseases: IgA nephropathy and primary membranous nephropathy. The study wi…

This early-phase trial tests a new type of immune cell therapy called UCAR-T for people with a tough-to-treat kidney condition called refractory idiopathic membranous nephropathy. The therapy uses specially engineered cells to target and attack certain immune cells that may be dr…

This early-stage trial tests a new drug called YK012 in 66 adults with a severe form of kidney disease called primary membranous nephropathy that has not responded to standard treatments. YK012 is a bispecific antibody designed to reduce the immune system's attack on the kidneys.…

Membranous nephropathy is a rare autoimmune kidney disease where antibodies attack the kidney and can cause nephrotic syndrome. Rituximab is a routine treatment that depletes B cells, but researchers suspect it also boosts regulatory T cells, which help control immune reactions. …

This study is testing whether a prediction model can accurately forecast how quickly kidney function declines in people with primary membranous nephropathy, a kidney disease that can lead to nephrotic syndrome and kidney failure. Researchers will follow 128 adults with biopsy-con…